Senseonics Holdings (NYSE: SENS) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $4.87 million versus the consensus estimate of $4.93 million.

GUIDANCE:

Senseonics Holdings sees FY2024 revenue of $22-24 million, versus the consensus of $25.085 million. The full year 2024 financial outlook assumes more than doubling the U.S. new patient starts and increasing the global installed base by approximately 50% in 2024 compared to 2023. Inventory dynamics associated with the 365-day product launch are expected to impact third quarter product sales, with sales expected to accelerate in the fourth quarter based on 365-day product sales and the Mercy collaboration. Cash utilization in 2024 is expected to be consistent with 2023 at approximately $70 million.

For earnings history and earnings-related data on Senseonics Holdings (SENS) click here.